Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"CYTX's upcoming ATHENA clinical data will be a major catalyst for the company, giving confidence not only to investors but also to the physician community." (11/14/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis Moreá>
"INO has extraordinary potential; I really want to see CEO Joseph Kim and Dave Weiner push this technology into the future." (10/24/13) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Patrick Cox Moreá>
"CPRX is an emerging biotechnology company in the white hot space of orphan drug medicines." (11/7/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Scott Henry Moreá>
"BDSI's buprenorphine product for chronic pain could be a $500M+/year revenue-generating drug if approved." (11/7/13) BioDelivery Sciences International Inc. - The Life Sciences Report Interview with Scott Henry Moreá>
Raghuram "Ram" Selvaraju's professional career started at the Geneva-based biotech firm Serono in 2000, where he discovered the first novel protein candidate developed entirely within the company. He subsequently became the youngest recipient of the company's Inventorship Award for Exceptional Innovation and Creativity. Selvaraju started in the securities industry with Rodman & Renshaw as a biotechnology equity research analyst. He was the top-ranked (#1) biotech analyst in The Wall Street Journal's "Best on the Street" survey (2006) and went on to become head of healthcare equity research at Hapoalim Securities, the New York-based broker/dealer subsidiary of Bank Hapoalim B. M., Israel's largest financial services group. While at Hapoalim, Selvaraju was regularly featured in The Wall Street Journal, Barron's, BioWorld Today, and Reuters/AP. He was also a regular guest on the Bloomberg TV program "Taking Stock," appeared with Bloomberg TV's on-air correspondents Betty Liu and Gigi Stone and was a guest on CNBC's "Street Signs with Herb Greenberg." He is currently an analyst with Aegis Capital Corp.
Not Your Father's Diagnostics: Ram Selvaraju on How Molecular Genomics Invigorate the Sector (12/5/13) An old investment principle says the equity upside of diagnostics and tools companies can't hold a candle to that of small biotech drug developers. Raghuram "Ram" Selvaraju, managing director and head of equity healthcare research at Aegis Capital, begs to differ. His research has uncovered small- and micro-cap companies developing sophisticated platforms in the molecular diagnostics space that are destined for significant revenue growth and profits. In his first of three interviews with The Life Sciences Report, Selvaraju lays out a handful of names with powerful technologies on the cusp of investor acceptance as huge growth plays.
Raghuram 'Ram' Selvaraju on the Best Biotech Ideas of 2013 (7/18/13) Small-cap, oncology-focused biotechs with novel technologies have always been bestsellers for investors. Subplots have emerged along the way, but Aegis Capital Corp.'s Managing Director and Head of Healthcare Equity Research Raghuram "Ram" Selvaraju maintains that these companies continue to drive the biotech story forward. In this interview with The Life Sciences Report, Selvaraju reflects on the state of the industry and shares reams of information on specific ideas for investors.
Ram Selvaraju: Fall in Love with These Nine Biotech Stocks (2/14/13) When it comes to unearthing dynamic micro-cap biotech investment opportunities, Ram Selvaraju is a master. Selvaraju, managing director and head of healthcare equity research at Aegis Capital Corp., has selected nine names destined to attract investors willing to take calculated risks, which he shares in this interview with The Life Sciences Report. He also explains why he expects 2013 will be another good year for the biotech industry.
"We have raised our 12-month price target for CPRX to $6/share; the profile for CPP-115 keeps getting better and better." (11/25/13) Catalyst Pharmaceutical Partners Inc. - Raghuram Selvaraju, Aegis Capital Corp. Moreá>
"CUR closed Q2/13 with $11.2M in cash and equivalents, which we anticipate to be sufficient to fund operations well into 2014." (8/16/13) Neuralstem Inc. - Raghuram Selvaraju, Aegis Capital Corp. Moreá>
"Firdapse could generate $80ľ100M in sales every year for CPRX, which has a $40M market cap." (7/18/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>
"We continue to be positive on GALE's NeuVax, which is proposed to prevent recurrence of breast cancer in disease-free patients." (7/18/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>
"CUR is one of the best stories in the stem cell arena and it has a rich calendar of catalysts in 2013 and into H1/14." (7/18/13) Neuralstem Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>
"Animal data has indicated LPTN's ASONEP™ may have activity in renal cell carcinoma, including that which is resistant to currently marketed drugs." (3/14/13) Lpath Inc. - Raghuram Selvaraju, Aegis Capital Corp. Moreá>
"VPT's technology platform is very interesting and is fundamentally underrated and misunderstood by the market." (11/1/12) VentriPoint Inc. - The Life Sciences Report Interview with Raghuram Selvaraju Moreá>
"CPRX has a few programs in indications that are less crowded and do not have many successful treatment options." (11/26/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Michael Hay Moreá>
"ATHX's MultiStem phase 2 data are going to be very important for investors if the trial is positive for patients." (11/26/13) Athersys Inc. - The Life Sciences Report Interview with Michael Hay Moreá>
"We expect FDA approval in the near termŚlikely by the end of the yearŚfor OCLS' Microcyn Hydrogel device." (11/26/13) Oculus Innovative Sciences Inc. - The Life Sciences Report Interview with Jocelyn August Moreá>